查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1434838

自体细胞治疗市场：按来源、适应症和最终用户划分 - 2024-2030 年全球预测

Autologous Cell Therapies Market by Source (Bone Marrow, Chondrocytes, Epidermis), Indication (Autoimmune Disorders, Cancer, Cardiovascular Disorders), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年自体细胞治疗市场规模为81.1亿美元，预计2024年将达92.4亿美元，2030年将达209.6亿美元，复合年增长率为14.52%。

自体细胞治疗的全球市场

主要市场统计
基准年[2023] 81.1亿美元
预测年份 [2024] 92.4亿美元
预测年份 [2030] 209.6亿美元
复合年增长率（%） 14.52%
自体细胞治疗市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估自体细胞治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对自体细胞治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-自体细胞治疗市场的市场规模与预测是多少？

2-自体细胞治疗市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3-自体细胞治疗市场的技术趋势和法律规范是什么？

4-自体细胞治疗市场主要厂商的市场占有率是多少？

5-进入自体细胞治疗市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地慢性病发生率上升
      • 扩大对新应用药物开发的关注
      • 随着医疗保健基础设施的改善，个人化医疗的需求增加
    • 抑制因素
      • 自体细胞疗法相关的高成本
    • 机会
      • 自体细胞治疗药物分散化生产技术的进步
      • 政府增加细胞研究的投资
    • 任务
      • 交货时间长和有效期有限的问题
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章自体细胞治疗市场：依来源分类

  • 骨髓
  • 软骨细胞
  • 表皮
  • 造血干细胞
  • 间质干细胞

第七章自体细胞治疗市场（按适应症）

  • 自体免疫疾病
  • 癌症
  • 心血管疾病
  • 神经退化性疾病
  • 整形外科
  • 创伤治疗

第八章自体细胞治疗市场：依最终使用者分类

  • 学术研究所
  • 门诊手术中心
  • 医院和诊所

第九章 美洲自体细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区自体细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲自体细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Abata Therapeutics
    • Achilles Therapeutics plc
    • Adaptimmune Therapeutics PLC
    • Adicet Bio Inc.
    • AIVITA Biomedical, Inc.
    • Aspen Neuroscienc Inc.
    • Bellicum Phamaceuticals, Inc.
    • BioLineRx Ltd.
    • BioSpace, Inc.
    • BrainStorm Cell Limited.
    • Bristol-Myers Squibb Company
    • Carisma Therapeutics Inc.
    • Catalent, Inc.
    • Cell Therapy Catapult Ltd.
    • Fate Therapeutics Inc.
    • GentiBio, Inc.
    • IASO BioTherapeutics
    • Kyverna Therapeutics, Inc.
    • NOVADIP Biosciences SA
    • Orchard Therapeutics Inc.
    • T-knife Therapeutics, Inc.
    • ThermoGenesis Holdings, Inc.
    • Triumvira Immunologics Inc.
    • Vita Therapeutics, Inc.
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-69324464D2C7

[192 Pages Report] The Autologous Cell Therapies Market size was estimated at USD 8.11 billion in 2023 and expected to reach USD 9.24 billion in 2024, at a CAGR 14.52% to reach USD 20.96 billion by 2030.

Global Autologous Cell Therapies Market

KEY MARKET STATISTICS
Base Year [2023] USD 8.11 billion
Estimated Year [2024] USD 9.24 billion
Forecast Year [2030] USD 20.96 billion
CAGR (%) 14.52%
Autologous Cell Therapies Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Autologous Cell Therapies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Autologous Cell Therapies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Autologous Cell Therapies Market, highlighting leading vendors and their innovative profiles. These include Abata Therapeutics, Achilles Therapeutics plc, Adaptimmune Therapeutics PLC, Adicet Bio Inc., AIVITA Biomedical, Inc., Aspen Neuroscienc Inc., Bellicum Phamaceuticals, Inc., BioLineRx Ltd., BioSpace, Inc., BrainStorm Cell Limited., Bristol-Myers Squibb Company, Carisma Therapeutics Inc., Catalent, Inc., Cell Therapy Catapult Ltd., Fate Therapeutics Inc., GentiBio, Inc., IASO BioTherapeutics, Kyverna Therapeutics, Inc., NOVADIP Biosciences S.A., Orchard Therapeutics Inc., T-knife Therapeutics, Inc., ThermoGenesis Holdings, Inc., Triumvira Immunologics Inc., and Vita Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Autologous Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Source
    • Bone Marrow
    • Chondrocytes
    • Epidermis
    • Haematopoietic Stem Cells
    • Mesenchymal Stem Cells
  • Indication
    • Autoimmune Disorders
    • Cancer
    • Cardiovascular Disorders
    • Neurodegenerative Disorders
    • Orthopedics
    • Wound Healing
  • End-User
    • Academics & Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Autologous Cell Therapies Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Autologous Cell Therapies Market?

3. What are the technology trends and regulatory frameworks in the Autologous Cell Therapies Market?

4. What is the market share of the leading vendors in the Autologous Cell Therapies Market?

5. Which modes and strategic moves are suitable for entering the Autologous Cell Therapies Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Autologous Cell Therapies Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in incidences of chronic diseases worldwide
      • 5.1.1.2. Expanding focus on drug development for new applications
      • 5.1.1.3. Growing need for personalized medicines with improving healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with autologous cell therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements for decentralizing manufacturing of autologous cell therapy
      • 5.1.3.2. Rising government investments in cell-based research
    • 5.1.4. Challenges
      • 5.1.4.1. Problems associated with long turnaround time and limited shelf life
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Autologous Cell Therapies Market, by Source

  • 6.1. Introduction
  • 6.2. Bone Marrow
  • 6.3. Chondrocytes
  • 6.4. Epidermis
  • 6.5. Haematopoietic Stem Cells
  • 6.6. Mesenchymal Stem Cells

7. Autologous Cell Therapies Market, by Indication

  • 7.1. Introduction
  • 7.2. Autoimmune Disorders
  • 7.3. Cancer
  • 7.4. Cardiovascular Disorders
  • 7.5. Neurodegenerative Disorders
  • 7.6. Orthopedics
  • 7.7. Wound Healing

8. Autologous Cell Therapies Market, by End-User

  • 8.1. Introduction
  • 8.2. Academics & Research Institutes
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Hospitals & Clinics

9. Americas Autologous Cell Therapies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autologous Cell Therapies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autologous Cell Therapies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abata Therapeutics
    • 13.1.2. Achilles Therapeutics plc
    • 13.1.3. Adaptimmune Therapeutics PLC
    • 13.1.4. Adicet Bio Inc.
    • 13.1.5. AIVITA Biomedical, Inc.
    • 13.1.6. Aspen Neuroscienc Inc.
    • 13.1.7. Bellicum Phamaceuticals, Inc.
    • 13.1.8. BioLineRx Ltd.
    • 13.1.9. BioSpace, Inc.
    • 13.1.10. BrainStorm Cell Limited.
    • 13.1.11. Bristol-Myers Squibb Company
    • 13.1.12. Carisma Therapeutics Inc.
    • 13.1.13. Catalent, Inc.
    • 13.1.14. Cell Therapy Catapult Ltd.
    • 13.1.15. Fate Therapeutics Inc.
    • 13.1.16. GentiBio, Inc.
    • 13.1.17. IASO BioTherapeutics
    • 13.1.18. Kyverna Therapeutics, Inc.
    • 13.1.19. NOVADIP Biosciences S.A.
    • 13.1.20. Orchard Therapeutics Inc.
    • 13.1.21. T-knife Therapeutics, Inc.
    • 13.1.22. ThermoGenesis Holdings, Inc.
    • 13.1.23. Triumvira Immunologics Inc.
    • 13.1.24. Vita Therapeutics, Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. AUTOLOGOUS CELL THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AUTOLOGOUS CELL THERAPIES MARKET DYNAMICS
  • FIGURE 7. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 8. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. AUTOLOGOUS CELL THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CHONDROCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY EPIDERMIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HAEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 150. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. AUTOLOGOUS CELL THERAPIES MARKET LICENSE & PRICING